Study ID: Children's Oncology Group (COG) - AAML1531NCT Number: <a href="https://clinicaltrials.gov/study/NCT02521493">NCT02521493</a>Trial Title: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Submitted in collaboration with the NCTN/NCORP Data ArchiveData presented in the following publication(s): <a href="https://pubmed.ncbi.nlm.nih.gov/34320162/">34320162</a> Disease type(s): Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia; Hematopoietic Neoplasm/Leukemia - Myelodysplastic SyndromeDataset(s) included:<ul><li>NCT02521493-D1: There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D1 dataset is a patient level dataset (single row per patient) containing patient characteristics, laboratory findings, and outcome for eligible myeloid leukemia in children with Down syndrome (ML-DS) enrolled on the AAML1531 clinical trial.</li><li>NCT02521493-D2: There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D2 dataset is an adverse event level dataset (single row per adverse event, period, and patient) containing information of the micro-organisms associated with adverse events by period in the AAML1531 clinical trial.</li></ul>

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531.